Literature DB >> 19734844

MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.

Nicholas J Hawkins1, James H-F Lee, Justin J-L Wong, Chau-To Kwok, Robyn L Ward, Megan P Hitchins.   

Abstract

O(6)-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that restores mutagenic O(6)-methylguanine to guanine. MGMT methylation is frequently observed in sporadic colorectal cancer and was recently correlated with the C>T allele at SNP rs16906252, within the transcriptional enhancer element of the promoter. MGMT methylation has also been associated with KRAS mutations, particularly G>A transitions. We studied 1123 colorectal carcinoma to define the molecular and clinicopathological profiles associated with MGMT methylation. Furthermore, we assessed factors contributing to MGMT methylation in the development of colorectal cancer by studying the allelic pattern of MGMT methylation using SNP rs16906252, and the methylation status of neighbouring genes within 10q26 in selected tumours and matched normal colonic mucosa. MGMT methylation was detected by combined bisulphite restriction analysis in 28% of tumours and was associated with a number of characteristics, including CDKN2A methylation, absent lymphovascular space invasion and KRAS mutations (but not specifically with KRAS G>A transitions). In a multivariate analysis adjusted for age and sex, MGMT methylation was associated with the T allele of SNP rs16906252 (P<0.0001, OR 5.5, 95% CI 3.8-7.9). Low-level methylation was detected by quantitative methylation-specific PCR in the normal colonic mucosa of cases, particularly those with a correspondingly methylated tumour, as well as controls without neoplasia, and this was also associated with the C>T SNP. We show that the T allele at SNP rs16906252 is a key determinant in the onset of MGMT methylation in colorectal cancer, whereas the association of methylation at MGMT and CDKN2A suggests that these loci may be targets of a common mechanism of epigenetic dysregulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734844     DOI: 10.1038/modpathol.2009.130

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  30 in total

Review 1.  Constitutional epimutation as a mechanism for cancer causality and heritability?

Authors:  Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 2.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

3.  Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer.

Authors:  Quan Wang; Peilin Jia; Feixiong Cheng; Zhongming Zhao
Journal:  Genes Chromosomes Cancer       Date:  2014-11-19       Impact factor: 5.006

4.  Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science.

Authors:  Shuji Ogino; Emily E King; Andrew H Beck; Mark E Sherman; Danny A Milner; Edward Giovannucci
Journal:  Am J Epidemiol       Date:  2012-08-30       Impact factor: 4.897

Review 5.  Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression.

Authors:  Paul Lochhead; Andrew T Chan; Reiko Nishihara; Charles S Fuchs; Andrew H Beck; Edward Giovannucci; Shuji Ogino
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

6.  The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.

Authors:  Shuguang Leng; Amanda M Bernauer; Chibo Hong; Kieu C Do; Christin M Yingling; Kristina G Flores; Mathewos Tessema; Carmen S Tellez; Randall P Willink; Elizabeth A Burki; Maria A Picchi; Christine A Stidley; Michael D Prados; Joseph F Costello; Frank D Gilliland; Richard E Crowell; Steven A Belinsky
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

7.  MGMT DNA repair gene promoter/enhancer haplotypes alter transcription factor binding and gene expression.

Authors:  Meixiang Xu; Courtney E Cross; Jordan T Speidel; Sherif Z Abdel-Rahman
Journal:  Cell Oncol (Dordr)       Date:  2016-06-15       Impact factor: 6.730

8.  The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

Authors:  Robert W Rapkins; Fan Wang; HuyTram N Nguyen; Timothy F Cloughesy; Albert Lai; Wendy Ha; Anna K Nowak; Megan P Hitchins; Kerrie L McDonald
Journal:  Neuro Oncol       Date:  2015-04-24       Impact factor: 12.300

9.  Statistical methods for studying disease subtype heterogeneity.

Authors:  Molin Wang; Donna Spiegelman; Aya Kuchiba; Paul Lochhead; Sehee Kim; Andrew T Chan; Elizabeth M Poole; Rulla Tamimi; Shelley S Tworoger; Edward Giovannucci; Bernard Rosner; Shuji Ogino
Journal:  Stat Med       Date:  2015-12-01       Impact factor: 2.373

10.  SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer.

Authors:  Joice Kuroiwa-Trzmielina; Fan Wang; Robert W Rapkins; Robyn L Ward; Daniel D Buchanan; Aung Ko Win; Mark Clendenning; Christophe Rosty; Melissa C Southey; Ingrid M Winship; John L Hopper; Mark A Jenkins; Jake Olivier; Nicholas J Hawkins; Megan P Hitchins
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.